APA (7th ed.) Citation

MW, S., JA, K., EG, C., SR, K., D, Y., B, P., . . . BH, O. (2016). Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer chemotherapy and pharmacology, 78(4), 815. https://doi.org/10.1007/s00280-016-3134-3

Chicago Style (17th ed.) Citation

MW, Saif, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, and O'Neil BH. "Phase 1 Study of the Anti-vascular Endothelial Growth Factor Receptor 3 Monoclonal Antibody LY3022856/IMC-3C5 in Patients with Advanced and Refractory Solid Tumors and Advanced Colorectal Cancer." Cancer Chemotherapy and Pharmacology 78, no. 4 (2016): 815. https://doi.org/10.1007/s00280-016-3134-3.

MLA (9th ed.) Citation

MW, Saif, et al. "Phase 1 Study of the Anti-vascular Endothelial Growth Factor Receptor 3 Monoclonal Antibody LY3022856/IMC-3C5 in Patients with Advanced and Refractory Solid Tumors and Advanced Colorectal Cancer." Cancer Chemotherapy and Pharmacology, vol. 78, no. 4, 2016, p. 815, https://doi.org/10.1007/s00280-016-3134-3.